131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.

@article{Pagel2006131IantiCD45AP,
  title={131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.},
  author={J. Pagel and F. Appelbaum and J. Eary and J. Rajendran and D. Fisher and T. Gooley and K. Ruffner and E. Nemecek and Eileen J. Sickle and L. Durack and J. Carreras and M. Horowitz and O. Press and A. Gopal and P. Martin and I. Bernstein and D. Matthews},
  journal={Blood},
  year={2006},
  volume={107 5},
  pages={
          2184-91
        }
}
  • J. Pagel, F. Appelbaum, +14 authors D. Matthews
  • Published 2006
  • Medicine
  • Blood
  • In an attempt to improve outcomes for patients with acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT), we conducted a phase 1/2 study in which targeted irradiation delivered by 131I-anti-CD45 antibody was combined with targeted busulfan (BU; area-under-curve, 600-900 ng/mL) and cyclophosphamide (CY; 120 mg/kg). Fifty-two (88%) of 59 patients receiving a trace 131I-labeled dose of 0.5 mg/kg anti-CD45 murine antibody had higher estimated absorbed radiation in… CONTINUE READING
    124 Citations
    90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma
    • 1
    Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.
    • R. Mawad, T. Gooley, +12 authors J. Pagel
    • Medicine
    • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
    • 2014
    • 39
    Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
    • 5

    References

    SHOWING 1-10 OF 74 REFERENCES
    Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias.
    • M. Schwartz, D. Lovett, +7 authors L. Old
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1993
    • 124
    Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    • 87
    Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
    • S. Knox, M. Goris, +12 authors R. Levy
    • Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 1996
    • 333